keyword
MENU ▼
Read by QxMD icon Read
search

RA nanomedicine

keyword
https://www.readbyqxmd.com/read/27237335/emerging-advances-innanomedicine-as-ananoscalepharmacotherapy-in-rheumatoid-arthritis-state-of-the-art
#1
Mahfoozur Rahman, Gajanand Sharma, Kanika Thakur, Vijay G Goni, Om Prakash Katare, Firoz Anwar, Vikas Kumar
Nanomedicines have been widely investigated for rheumatoid arthritis (RA). There are several significant setbacks including limited bioavailability, high clearance, and further current therapies require higher and frequent dosing to gain desired therapeutic effects. Though, higher doses also increase the incidence of dreadful adverse effects. Further, nanocarrier properties are tuned by the use of different approaches likevaried methods of loading, hydrophilic polymers and targeting ligands, to change the physicochemical properties including higher encapsulation, better penetrating ability to biological barriers, thus preventing the uptake of various nanocarriers by liver and spleen...
May 30, 2016: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/26087258/solid-lipid-nanoparticles-a-potential-multifunctional-approach-towards-rheumatoid-arthritis-theranostics
#2
João Albuquerque, Catarina Costa Moura, Bruno Sarmento, Salette Reis
Rheumatoid arthritis (RA) is the most common joint-related autoimmune disease and one of the most severe. Despite intensive investigation, the RA inflammatory process remains largely unknown and finding effective and long lasting therapies that specifically target RA is a challenging task. This study proposes a different approach for RA therapy, taking advantage of the new emerging field of nanomedicine to develop a targeted theranostic system for intravenous administration, using solid lipid nanoparticles (SLN), a biocompatible and biodegradable colloidal delivery system, surface-functionalized with an anti-CD64 antibody that specifically targets macrophages in RA...
2015: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://www.readbyqxmd.com/read/26001074/drug-loaded-gold-iron-gold-plasmonic-nanoparticles-for-magnetic-targeted-chemo-photothermal-treatment-of-rheumatoid-arthritis
#3
Hyung Joon Kim, Sun-Mi Lee, Kyu-Hyung Park, Chin Hee Mun, Yong-Beom Park, Kyung-Hwa Yoo
We have developed methotrexate (MTX)-loaded poly(lactic-co-glycolic acid, PLGA) gold (Au)/iron (Fe)/gold (Au) half-shell nanoparticles conjugated with arginine-glycine-aspartic acid (RGD), which can be applied for magnetic targeted chemo-photothermal treatment, and in vivo multimodal imaging of rheumatoid arthritis (RA). Upon near-infrared (NIR) irradiation, local heat is generated at the inflammation region due to the NIR resonance of Au half-shells and MTX release from PLGA nanoparticles is accelerated. The Fe half-shell layer embedded between the Au half-shell layers enables in vivo T2-magnetic resonance (MR) imaging in addition to NIR absorbance imaging...
August 2015: Biomaterials
https://www.readbyqxmd.com/read/25986584/cutaneous-penetration-of-soft-nanoparticles-via-photodamaged-skin-lipid-based-and-polymer-based-nanocarriers-for-drug-delivery
#4
Chi-Feng Hung, Wei-Yu Chen, Ching-Yun Hsu, Ibrahim A Aljuffali, Hui-Chi Shih, Jia-You Fang
Photoaging is recognized as the factor damaging skin-barrier function. The aim of this study was to examine the impact of ultraviolet (UV) irradiation on the cutaneous penetration of soft nanoparticles, including nanostructured lipid carriers (NLCs) and poly(lactic-co-glycolic acid) polymer nanoparticles (PNs). In vitro cutaneous permeation of retinoic acid (RA) carried by nanoparticles was evaluated. In vivo nude mouse skin distribution of topically applied nanoparticles was observed by fluorescence and confocal microscopies...
August 2015: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/25979151/temperature-responsive-polymeric-nanospheres-containing-methotrexate-and-gold-nanoparticles-a-multi-drug-system-for-theranostic-in-rheumatoid-arthritis
#5
Sofia A Costa Lima, Salette Reis
Inflammation plays a crucial role in rheumatoid arthritis progress. In the present work, a novel stealth polymeric nanospheres platform able to carry anti-inflammatory drugs and an imaging agent was developed. Incorporation of gold nanoparticles will allow photoacoustic imaging and near infra-red photothermal application. Through emulsion-diffusion evaporation technique methotrexate and gold nanoparticles were incorporated in the pegylated-poly(DL-lactic-co-glycolic acid) nanospheres. In vitro drug release assays revealed pH and temperature-dependence on gold nanoparticles...
September 1, 2015: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/24941020/fumagillin-prodrug-nanotherapy-suppresses-macrophage-inflammatory-response-via-endothelial-nitric-oxide
#6
Hui-fang Zhou, Huimin Yan, Ying Hu, Luke E Springer, Xiaoxia Yang, Samuel A Wickline, Dipanjan Pan, Gregory M Lanza, Christine T N Pham
Antiangiogenesis has been extensively explored for the treatment of a variety of cancers and certain inflammatory processes. Fumagillin, a mycotoxin produced by Aspergillus fumigatus that binds methionine aminopeptidase 2 (MetAP-2), is a potent antiangiogenic agent. Native fumagillin, however, is poorly soluble and extremely unstable. We have developed a lipase-labile fumagillin prodrug (Fum-PD) that eliminated the photoinstability of the compound. Using αvβ3-integrin-targeted perfluorocarbon nanocarriers to deliver Fum-PD specifically to angiogenic vessels, we effectively suppressed clinical disease in an experimental model of rheumatoid arthritis (RA)...
July 22, 2014: ACS Nano
https://www.readbyqxmd.com/read/23211088/novel-biocompatible-and-disease-modifying-vip-nanomedicine-for-rheumatoid-arthritis
#7
Varun Sethi, Israel Rubinstein, Antonina Kuzmis, Helen Kastrissios, James Artwohl, Hayat Onyuksel
Despite advances in rheumatoid arthritis (RA) treatment, efficacious and safe disease-modifying therapy still represents an unmet medical need. Here, we describe an innovative strategy to treat RA by targeting low doses of vasoactive intestinal peptide (VIP) self-associated with sterically stabilized micelles (SSMs). This spontaneous interaction of VIP with SSM protects the peptide from degradation or inactivation in biological fluids and prolongs circulation half-life. Treatment with targeted low doses of nanosized SSM-VIP but not free VIP in buffer significantly reduced the incidence and severity of arthritis in an experimental model, completely abrogating joint swelling and destruction of cartilage and bone...
February 4, 2013: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/22640912/nanomedicines-for-chronic-non-infectious-arthritis-the-clinician-s-perspective
#8
REVIEW
Israel Rubinstein, Guy L Weinberg
Rheumatoid arthritis (RA) and osteoarthritis (OA) are prevalent chronic health conditions. However, despite recent advances in medical therapeutics, their treatment still represents an unmet medical need because of safety and efficacy concerns with currently prescribed drugs. Accordingly, there is an urgent need to develop and test new drugs for RA and OA that selectively target inflamed joints thereby mitigating damage to healthy tissues. Conceivably, biocompatible, biodegradable, disease-modifying antirheumatic nanomedicines (DMARNs) could represent a promising therapeutic approach for RA and OA...
September 2012: Nanomedicine: Nanotechnology, Biology, and Medicine
https://www.readbyqxmd.com/read/22264497/nanomedicines-for-chronic-non-infectious-arthritis-the-clinician-s-perspective
#9
REVIEW
Israel Rubinstein, Guy L Weinberg
Rheumatoid arthritis (RA) and osteoarthritis (OA) are prevalent chronic health conditions. However, despite recent advances in medical therapeutics, their treatment still represents an unmet medical need because of safety and efficacy concerns with currently prescribed drugs. Accordingly, there is an urgent need to develop and test new drugs for RA and OA that selectively target inflamed joints thereby mitigating damage to healthy tissues. Conceivably, biocompatible, biodegradable, disease-modifying antirheumatic nanomedicines (DMARNs) could represent a promising therapeutic approach for RA and OA...
September 2012: Maturitas
https://www.readbyqxmd.com/read/21837725/nanotherapeutic-approaches-for-the-treatment-of-rheumatoid-arthritis
#10
REVIEW
Christine T N Pham
Rheumatoid arthritis (RA) is a common inflammatory disease characterized by progressive bone and cartilage destruction, resulting in severe functional limitations, shortened lifespan, and increased mortality rates. Recent advances and new treatment approaches have significantly delayed disease progression and improved the quality of life for many patients. Yet few patients attain or can be maintained in disease remission without continuous immunosuppressive therapy. In addition, a sizable portion of patients also fails to respond or eventually develops tolerance to current therapies...
November 2011: Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology
https://www.readbyqxmd.com/read/21132352/actively-targeted-low-dose-camptothecin-as-a-safe-long-acting-disease-modifying-nanomedicine-for-rheumatoid-arthritis
#11
Otilia May Yue Koo, Israel Rubinstein, Hayat Onyüksel
PURPOSE: Camptothecin (CPT), a potent topoisomerase I inhibitor, was originally discovered as an anticancer agent to induce programmed cell death of cancer cells. Recent evidence suggests that, similar to cancer, alterations in apoptosis and over-proliferation of key effector cells in the arthritic joint result in rheumatoid arthritis (RA) pathogenesis. Initial in vitro studies have suggested that camptothecin inhibits synoviocyte proliferation, matrix metalloproteinases expression in chrondrocytes and angiogenesis...
April 2011: Pharmaceutical Research
https://www.readbyqxmd.com/read/17722505/targeting-nanomedicines-in-the-treatment-of-rheumatoid-arthritis-focus-on-certolizumab-pegol
#12
REVIEW
Theresa Barnes, Robert Moots
Anti-TNFalpha therapy has revolutionized the treatment of rheumatoid arthritis (RA) and other inflammatory diseases. These drugs are powerful and expensive. A new anti-TNFalpha agent, a nanomolecule comprising a humanized Fab' antibody fragment against TNFalpha with a polyethylene glycol tail, is shortly to complete phase III trials in RA. In this review we will discuss the construct of this new molecule, data from trials so far, and its potential place in the market place.
2007: International Journal of Nanomedicine
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"